Uracyl Spirooxetane Nucleosides
    36.
    发明公开
    Uracyl Spirooxetane Nucleosides 有权
    尿嘧啶 - spirooxetan-nukleoside

    公开(公告)号:EP2511282A1

    公开(公告)日:2012-10-17

    申请号:EP12176402.1

    申请日:2010-05-11

    摘要: Compounds of the formula I:

    including any possible stereoisomers thereof, wherein:
    R 4
    is a monophosphate, diphosphate or triphosphate ester; or R 4 is

    R 7
    is optionally substituted phenyl, optionally substituted naphthyl, or optionally substituted indolyl;
    R 8 and R 8'
    are hydrogen, C 1 -C 6 alkyl, benzyl, or phenyl; or R 8 and R 8' form C 3 -C 7 cycloalkyl;
    R 9
    is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, phenyl or phenyl-C 1 -C 6 alkyl, wherein the phenyl moiety in phenyl or phenyl-C 1 -C 6 alkyl is optionally substituted;

    or a pharmaceutically acceptable salt or solvate thereof;
    pharmaceutical formulations and the use of compounds I as HCV inhibitors.

    摘要翻译: 式I化合物:包括其任何可能的立体异构体,其中:R 4是单磷酸酯,二磷酸酯或三磷酸酯; 或R 4为R 7为任选取代的苯基,任选取代的萘基或任选取代的吲哚基; R 8和R 8'是氢,C 1 -C 6烷基,苄基或苯基; 或R 8和R 8'形成C 3 -C 7环烷基; R 9是C 1 -C 10烷基,C 3 -C 7环烷基,苯基或苯基-C 1 -C 6烷基,其中苯基或苯基-C 1 -C 6烷基中的苯基部分任选被取代; 或其药学上可接受的盐或溶剂化物; 药物制剂和化合物I作为HCV抑制剂的用途。